

Remarks

I. Restriction and Election Requirement

In the above referenced Office Action, the Examiner divided the claims into the following groups:

Group I.: Claims 1-13, drawn to a composition comprising urease and a targeting moiety and a kit for use in inhibiting growth of cancer cells in a mammalian subject, classified in class 424, subclass 94.6;

Group II.: Claims 14-33, drawn to a method for inhibiting growth of cancer cells in a mammalian subject, classified in class 424, subclass 94.6;

Group III.: Claims 34-38, drawn to a method of enhancing the therapeutic efficacy of a weakly basic anti-tumor compound whose effectiveness is reduced by a higher intracellular/lower extracellular pH gradient in a solid tumor, classified in class 424, subclass 94.6;

Group IV.: Claims 39-43, drawn to a method of assessing the presence, size or condition of a solid tumor in a subject, classified in class 435, subclass 18; and

Group V.: Claims 48-50, drawn to a gene therapy composition, classified in class 514, subclass 44.

In response, Applicants elect to begin prosecution with examination of claim **Group I**, claims 1-13, without traverse. Non-elected claims 14-50 are withdrawn from consideration.

Applicants reserve the right to file divisional applications directed to the non-elected claims of Group II., III., IV., and V.

II. Amendments

Non-elected claims 14-50 are withdrawn from consideration.

No new matter is added by way of these amendments.

If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 838-4341.

Respectfully submitted,

Gina C. Freschi

Gina C. Freschi
Registration No. 52,062

Date: March 7, 2006

Correspondence Address:

Customer No. 22918

Direct Tel: 650 838-4341

Direct Fax: 650 838-4541